Loading
A phase 2 trial of PM8002 and Etoposide in small-cell lung cancer, run by Biotheus Inc., active and no longer recruiting.
A Study of PM8002 (Anti-PD-L1/VEGF) in Combination With Chemotherapy in Patients With ES-SCLC is a phase 2 interventional study registered as NCT05844150 by Biotheus Inc., with 50 participants enrolled, started 2023-06-01 and due to reach its primary completion in 2024-05-10. Interventions recorded: PM8002, Platinum and Etoposide.
Shares PM8002, BioNTech, Small-cell lung cancer and the tag pipeline.
Shares Etoposide, Topoisomerase-I inhibitors (and ADC payloads), Small-cell lung cancer, Cytotoxic chemotherapy and the tag pipeline.
Shares Extensive-stage small-cell lung cancer, Etoposide, Topoisomerase-I inhibitors (and ADC payloads), Small-cell lung cancer and the tag pipeline.